Abaxis, Inc. develops, manufactures, markets, and sells portable blood analysis systems for use in human or veterinary patient care to provide rapid blood constituent measurements for clinicians worldwide. It operates in two segments, Medical Market and Veterinary Market. The company offers Piccolo chemistry analyzers with rapid blood constituent measurements for use in human patient care; and Piccolo profiles that are single-use medical reagents. It also provides VetScan VS2, a chemistry, electrolyte, immunoassay, and blood gas analyzer delivering results from a sample of whole blood, serum, or plasma; VetScan profiles, which are packaged as single-use plastic veterinary reagent discs; and VetScan HM5, VetScan HM2, VetScan HMII, and VetScan HMT hematology instruments, as well as reagent kits for veterinary applications. In addition, the company offers VetScan VSpro that assists the diagnosis and evaluation of suspected bleeding disorders, toxicity/poisoning, disseminated intravascular coagulation evaluation, hepatic disease, monitoring therapy, and disease progression states; VetScan VSpro coagulation test to evaluate prothrombin and the activated partial thromboplastin times; VetScan VSpro fibrinogen test for in-vitro determination of fibrinogen levels in equine platelet poor plasma from a citrated stabilized whole blood sample; i-STAT that delivers blood gas, electrolyte, chemistry, and hematology results; VetScan UA, a urinalysis solution; and VetScan SA, which is designed to perform urine microscopy. Further, it provides VetScan rapid tests for the detection of various diseases, as well as sells products developed through its patented Orbos discrete lyophilization process to companies for other applications. The company sells its products through direct sales force and independent distributors. Abaxis, Inc. was founded in 1989 and is headquartered in Union City, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Measuring & controlling devices, not elsewhere classified
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:ABAX
Previous Symbol
CUSIP00256710
Phone510-675-6500
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees656
Outstanding SharesN/A
Market Cap$0.00
OptionableOptionable
Abaxis (NASDAQ:ABAX) Frequently Asked Questions
What is Abaxis' stock symbol?
Abaxis trades on the NASDAQ under the ticker symbol "ABAX."
How often does Abaxis pay dividends? What is the dividend yield for Abaxis?
Abaxis announced a quarterly dividend on Thursday, April 26th. Investors of record on Friday, June 1st will be paid a dividend of $0.18 per share on Friday, June 15th. This represents a $0.72 annualized dividend and a yield of 0.87%. The ex-dividend date is Thursday, May 31st. This is a boost from Abaxis's previous quarterly dividend of $0.16. View Abaxis' Dividend History.
How will Abaxis' stock buyback program work?
Abaxis announced that its Board of Directors has approved a stock buyback plan on Wednesday, October 25th 2017, which permits the company to repurchase $21,000,000.00 in shares, according to EventVestor. This repurchase authorization permits the company to reacquire shares of its stock through open market purchases. Stock repurchase plans are often an indication that the company's leadership believes its shares are undervalued.
How were Abaxis' earnings last quarter?
Abaxis Inc (NASDAQ:ABAX) issued its quarterly earnings results on Thursday, April, 26th. The medical research company reported $0.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.32 by $0.10. The medical research company earned $67.90 million during the quarter, compared to analyst estimates of $66.02 million. The firm's revenue was up 16.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.33 EPS. View Abaxis' Earnings History.
What price target have analysts set for ABAX?
9 Wall Street analysts have issued 12-month price objectives for Abaxis' stock. Their forecasts range from $48.00 to $65.00. On average, they expect Abaxis' share price to reach $58.3333 in the next twelve months. This suggests that the stock has a possible downside of 29.7%. View Analyst Price Targets for Abaxis.
What is the consensus analysts' recommendation for Abaxis?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Abaxis in the last year. There are currently 1 sell rating, 7 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Abaxis.
Has Abaxis been receiving favorable news coverage?
Headlines about ABAX stock have trended somewhat positive recently, InfoTrie reports. InfoTrie rates the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Abaxis earned a media sentiment score of 1.6 on InfoTrie's scale. They also gave news coverage about the medical research company a news buzz of 2.0 out of 10, indicating that recent media coverage is very unlikely to have an effect on the stock's share price in the immediate future.
Who are some of Abaxis' key competitors?
Some companies that are related to Abaxis include Thermo Fisher Scientific (TMO), Rockwell Automation (ROK), Trimble (TRMB), MEGGITT PLC/ADR (MEGGY), Cubic (CUB), MTS Systems (MTSC), FARO Technologies (FARO), Nanometrics (NANO), Oxford Instruments (OXINF), Geospace Technologies (GEOS), Know Labs (KNWN), Image Sensing Systems (ISNS), Midwest Energy Emissions (MEEC), Sierra Monitor (SRMC) and Cemtrex (CETX).
Who are Abaxis' key executives?
Abaxis' management team includes the folowing people:
- Mr. Clinton H. Severson, Chairman & CEO (Age 70)
- Mr. Donald P. Wood, Pres & COO (Age 66)
- Mr. Ross Taylor Jr., CFO, VP of Fin. & Sec. (Age 55)
- Dr. Kenneth P. Aron Ph.D., Chief Technology Officer (Age 65)
- Dr. Craig M. Tockman DVM, VP of Animal Health Sales and Marketing - North America (Age 58)
How do I buy shares of Abaxis?
Shares of ABAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Abaxis' stock price today?
One share of ABAX stock can currently be purchased for approximately $83.00.
What is Abaxis' official website?
How can I contact Abaxis?
Abaxis' mailing address is 3240 WHIPPLE ROAD, UNION CITY CA, 94587. The medical research company can be reached via phone at 510-675-6500 or via email at [email protected]com.
MarketBeat Community Rating for Abaxis (NASDAQ ABAX)
MarketBeat's community ratings are surveys of what our community members think about Abaxis and other stocks. Vote "Outperform" if you believe ABAX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABAX will underperform the S&P 500 over the long term. You may vote once every thirty days.
